Bristol-Myers Squibb Names Elliott Sigal, M.D., Ph.D., to Board of Directors

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) today announced that Elliott Sigal, M.D., Ph.D., has been elected to its Board of Directors, effective today. Dr. Sigal also will be a member of the Board’s Science and Technology Committee.

Dr. Sigal, 59, reports to Lamberto Andreotti, chief executive officer, as executive vice president, chief scientific officer and president, Bristol-Myers Squibb Research and Development, a position he has held since 2004. Dr. Sigal joined Bristol-Myers Squibb in November 1997 as vice president of Applied Genomics. Since then he has served in critical leadership roles within R&D, including drug discovery and development. During Dr. Sigal’s tenure as chief scientific officer, Bristol-Myers Squibb achieved eight new drug approvals and the R&D organization filled the drug pipeline with an unprecedented number of mid- and late-stage assets, five of which could be approved by 2012.

“We are very excited to have Elliott join our Board,” said James M. Cornelius, chairman, Bristol-Myers Squibb. “Under his leadership, our R&D organization has become one of the most productive in the industry. Today’s appointment recognizes his great contribution to the company.”

“Elliott’s election to our Board recognizes the importance of R&D to our strategy and our success as a BioPharma company,” added Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “Elliott is an important member of my Senior Management Team, a team that joins me in congratulating him on this great honor and his many accomplishments.”

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb
Media: Tracy Furey, 609-252-3208
[email protected]
or
Investors: John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.